Randomized, open-label phase 2 study comparing frontline dovitinib versus sorafenib in patients with advanced hepatocellular carcinoma
出版年份 2016 全文链接
标题
Randomized, open-label phase 2 study comparing frontline dovitinib versus sorafenib in patients with advanced hepatocellular carcinoma
作者
关键词
-
出版物
HEPATOLOGY
Volume 64, Issue 3, Pages 774-784
出版商
Wiley
发表日期
2016-04-15
DOI
10.1002/hep.28600
参考文献
相关参考文献
注意:仅列出部分参考文献,下载原文获取全部文献信息。- Post-progression survival in patients with advanced hepatocellular carcinoma resistant to sorafenib
- (2016) Sadahisa Ogasawara et al. INVESTIGATIONAL NEW DRUGS
- A randomized, crossover phase 1 study to assess the effects of formulation (capsule vs tablet) and meal consumption on the bioavailability of dovitinib (TKI258)
- (2015) Jeffrey R. Infante et al. CANCER CHEMOTHERAPY AND PHARMACOLOGY
- Refining sorafenib therapy: lessons from clinical practice
- (2015) Luigi Bolondi et al. Future Oncology
- Linifanib Versus Sorafenib in Patients With Advanced Hepatocellular Carcinoma: Results of a Randomized Phase III Trial
- (2015) Calin Cainap et al. JOURNAL OF CLINICAL ONCOLOGY
- Surgical Treatment for Hepatocellular Carcinoma
- (2015) MazenM Hassanain et al. Saudi Journal of Gastroenterology
- Phase 2 trial of dovitinib in patients with progressive FGFR3-mutated or FGFR3 wild-type advanced urothelial carcinoma
- (2014) Matthew I. Milowsky et al. EUROPEAN JOURNAL OF CANCER
- Sa1701 Cytotoxic T Lymphocyte Antigen-4 (Ctla-4) Signaling Effectively Retains Regulatory T Cells (Treg) to Alleviate Liver Injury of Patients With Acute-on-Chronic Hepatitis B (Achb)
- (2014) Jing Li et al. GASTROENTEROLOGY
- Development of systemic therapy for hepatocellular carcinoma at 2013: Updates and insights
- (2014) Stephen L Chan WORLD JOURNAL OF GASTROENTEROLOGY
- Phase II study of dovitinib in patients with metastatic and/or unresectable gastrointestinal stromal tumours after failure of imatinib and sunitinib
- (2013) Y-K Kang et al. BRITISH JOURNAL OF CANCER
- Phase I Study of Dovitinib (TKI258), an Oral FGFR, VEGFR, and PDGFR Inhibitor, in Advanced or Metastatic Renal Cell Carcinoma
- (2013) E. Angevin et al. CLINICAL CANCER RESEARCH
- Targeting FGFR with Dovitinib (TKI258): Preclinical and Clinical Data in Breast Cancer
- (2013) F. Andre et al. CLINICAL CANCER RESEARCH
- Brivanib Versus Sorafenib As First-Line Therapy in Patients With Unresectable, Advanced Hepatocellular Carcinoma: Results From the Randomized Phase III BRISK-FL Study
- (2013) Philip J. Johnson et al. JOURNAL OF CLINICAL ONCOLOGY
- Sunitinib Versus Sorafenib in Advanced Hepatocellular Cancer: Results of a Randomized Phase III Trial
- (2013) Ann-Lii Cheng et al. JOURNAL OF CLINICAL ONCOLOGY
- Plasma Biomarkers as Predictors of Outcome in Patients with Advanced Hepatocellular Carcinoma
- (2012) J. M. Llovet et al. CLINICAL CANCER RESEARCH
- A Novel Monoclonal Antibody to Fibroblast Growth Factor 2 Effectively Inhibits Growth of Hepatocellular Carcinoma Xenografts
- (2012) L. Wang et al. MOLECULAR CANCER THERAPEUTICS
- Phase I/II and Pharmacodynamic Study of Dovitinib (TKI258), an Inhibitor of Fibroblast Growth Factor Receptors and VEGF Receptors, in Patients with Advanced Melanoma
- (2011) K. B. Kim et al. CLINICAL CANCER RESEARCH
- Management of hepatocellular carcinoma: An update
- (2011) Jordi Bruix et al. HEPATOLOGY
- Dovitinib demonstrates antitumor and antimetastatic activities in xenograft models of hepatocellular carcinoma
- (2011) Hung Huynh et al. JOURNAL OF HEPATOLOGY
- Dovitinib Induces Apoptosis and Overcomes Sorafenib Resistance in Hepatocellular Carcinoma through SHP-1-Mediated Inhibition of STAT3
- (2011) W.-T. Tai et al. MOLECULAR CANCER THERAPEUTICS
- Up-regulation of the fibroblast growth factor 8 subfamily in human hepatocellular carcinoma for cell survival and neoangiogenesis
- (2010) Christine Gauglhofer et al. HEPATOLOGY
- A Phase I Pharmacokinetic and Pharmacodynamic Study of TKI258, an Oral, Multitargeted Receptor Tyrosine Kinase Inhibitor in Patients with Advanced Solid Tumors
- (2008) D. Sarker et al. CLINICAL CANCER RESEARCH
- Design and Endpoints of Clinical Trials in Hepatocellular Carcinoma
- (2008) Josep M. Llovet et al. JNCI-Journal of the National Cancer Institute
- Efficacy and safety of sorafenib in patients in the Asia-Pacific region with advanced hepatocellular carcinoma: a phase III randomised, double-blind, placebo-controlled trial
- (2008) Ann-Lii Cheng et al. LANCET ONCOLOGY
- Sorafenib in Advanced Hepatocellular Carcinoma
- (2008) Josep M. Llovet et al. NEW ENGLAND JOURNAL OF MEDICINE
Create your own webinar
Interested in hosting your own webinar? Check the schedule and propose your idea to the Peeref Content Team.
Create NowAsk a Question. Answer a Question.
Quickly pose questions to the entire community. Debate answers and get clarity on the most important issues facing researchers.
Get Started